RPS6 and cancer: RPS6, 70 kDa, polypeptide 2 (RPS6KB2) and PTEN were strongly associated with the activation of the mTOR signaling pathway in cancer, while mTOR pathway activation demonstrated higher expression of RPS6K, S6, 4E-BP1 and eIF-4G, linked with more aggressive clinical behavior [29].